Sierra Oncology (SRRA) Financials

$54.99

$0.00 (0.00%)

As on 01-Jul-2022 09:30EDT

Market cap

$1,343 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

5.1

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	--	--	0.30	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	0.00	--	--	--
Operating Expenses	102.65	94.59	65.24	66.99	55.42	42.62
Operating Profit (EBIT)	-102.65	-94.59	-64.94	-66.99	-55.42	-42.62
Other Income	-0.11	-0.08	-15.82	-21.44	1.78	0.76
Profit before Tax	-102.76	-94.66	-80.76	-88.44	-53.64	-41.86
Provision for Tax	-0.09	0.00	0.14	-0.16	-0.30	0.16
Profit after Tax (Net Income)	-102.67	-94.66	-80.90	-88.28	-53.34	-42.02
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-102.67	-94.66	-80.90	-88.28	-53.34	-42.02

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	261.62	96.00	97.96	86.35	94.48	94.73
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	5.30	0.49	0.18	0.37	4.89	--
Current Liabilities	13.08	12.88	9.35	64.61	10.10	7.47
Total Liabilities	293.08	109.37	107.49	151.33	109.47	102.20

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	1.80	1.97	1.02	1.43	0.72	0.47
Current Assets	278.20	107.39	106.47	149.90	108.75	101.73
Total Assets	293.08	109.37	107.49	151.33	109.47	102.20
Total Debt*	5.62	0.85	0.38	0.56	4.89	--
Net Current Assets	265.12	94.51	97.12	85.29	98.65	94.25

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-78.96	-52.37	-51.18	-45.12	-36.16
Cash Flow from Investing Activities	--	-0.07	-0.01	-0.04	-0.12	-0.09
Cash from Financing Activities	--	79.81	8.90	92.74	51.13	27.59
Net Cash Inflow / Outflow	--	0.77	-43.48	41.52	5.90	-8.66

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	-7.05	-7.28	-7.35	-29.43	-26.67	-42.02
Cash EPS ($)	--	-7.26	-7.33	-29.40	-26.61	-41.76
Adjusted Book Value ($)	--	7.38	8.91	28.78	47.24	94.73
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-6.07	-4.76	-17.06	-22.56	-36.16
Free Cash Flow per Share ($)	--	-6.08	-4.76	-17.07	-22.62	-36.26

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-96.99	-87.35	-94.78	-54.96	-42.44
ROE (%)	-57.57	-97.61	-87.79	-97.64	-56.38	-42.44
ROA (%)	-49.78	-87.30	-62.52	-67.70	-50.40	-39.42
EBIT Margin (%)	--	--	-26,920.00	--	--	--
Net Margin (%)	95,955.14	122,933.77	521.31	411.67	-2,996.35	-5,528.29
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	--	-1.00	--	--	--	--
EBIT Growth (%)	-49.37	-17.12	-75.31	16.87	-30.03	11.35
Net Profit Growth (%)	-49.01	-17.00	8.35	-65.51	-26.94	12.23
EPS Growth (%)	-10.31	0.01	0.75	-0.10	0.37	0.12
Book Value Growth (%)	47.21	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	-2.99	-2.18	-0.01	-0.05	-0.09
Price / Book Value	5.13	2.94	1.80	0.01	0.03	0.04
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-10.50	-1.90	-0.90	3.17	1.78	2.28
Close Price ($)	32.05	21.74	16.03	13.70	52.80	149.20
High Price ($)	37.33	24.00	19.68	80.40	154.40	163.60
Low Price ($)	14.91	13.68	8.55	8.62	41.93	44.00
Market Cap ($ Cr)	1,342.82	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	0.02	0.01	0.00	0.01	0.05	--
Short term debt to equity ratio	0.00	0.00	0.00	0.00	--	--
Current Ratio	21.27	8.34	11.38	2.32	10.77	13.61
Quick Ratio	21.27	--	--	--	--	13.61
Interest Coverage	--	--	--	--	--	--

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	--	--	103.67	--	--	--
Asset Turnover	--	--	0.00	--	--	--
Receivable days	--	--	309.25	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.